An observational study in Cardiac Disease, sponsored by Mayo Clinic. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-08.
Sponsored by Mayo Clinic · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Heart Diseases by Mayo Clinic — 3 open to participants now, 4 under way, none of them phase 3. Heart Diseases · Mayo Clinic.
Among the 22 studies in Heart Diseases by Mayo Clinic, this one is the only one that started in 2025, is one of 14 observational ones, and was the 20th registered.
2,135 studies on the registry are indexed under Heart Diseases; 250 are open to participants now.
Browse Heart Diseases studies →3 of the 22 studies in Heart Diseases by Mayo Clinic are open now, in 2 countries. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 18+
Mayo Clinic · Sites in United States, United Kingdom
Healthy volunteers
Mayo Clinic · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 182 Heart Diseases studies recruiting now, 128 (70%) set no upper age limit and 22 (12%) stop at 75 or younger; 33 take children under 18; 41 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 3 · Phase 3 1
First in 1997; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 2,705 is above the median of 350 across 592 observational studies indexed under Heart Diseases.
Median enrollment 42 across the 8 interventional studies, 1,200 across the 9 observational. Of the 16 that completed or were terminated, 2 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
Mayo Clinic is the lead sponsor of 3,272 studies on the registry; 672 are open to participants now.
Of its 452 completed or terminated interventional studies of FDA-regulated products, 322 (71%) have results posted.
2 of the studies in Heart Diseases by Mayo Clinic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06891222Mayo ClinicA Study of Electrocardiogram and Focused Cardiac Ultrasound for Enhanced Cardiac Disease Screening | 2026-11 |
| NCT03049254Mayo ClinicMayo AVC Registry and Biobank | 2027-03 |
Add all 2 to your calendar (.ics) → With an account.
Among the 22 studies in Heart Diseases by Mayo Clinic, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate and compare the effectiveness of active screening for SHD in asymptomatic outpatients referred for an ECG, using a combination of AI-ECG and FOCUS. Invites will be sent and participants enrolled electronically.
All subjects aged 18 or older without known congenital or acquired SHD scheduled to undergo an elective outpatient electrocardiogram
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Prior history of congenital or acquired SHD, as defined by the following
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Diagnostic Test: AI-ECG (artificial intelligence-enabled electrocardiogram) · Diagnostic Test: Focus Screening (focused cardiac ultrasonography)
Participants will undergo electrocardiogram analysis using AI-ECG during the baseline visit
Participants will undergo a focused cardiac ultrasound if the AI-ECG reflects a positive value
Percentage of subjects to be diagnosed with SHD (structural heart disease)
Percentage of subjects to be diagnosed with SHD will be determined by the number of subjects that have a positive SHD screening. Positive SHD screening is defined by any one of the following: decreased LVEF (left ventricular ejection fraction), cardiac amyloidosis, aortic stenosis, and hypertrophic cardiomyopathy.
Time frame: Baseline, 6 months, 1 year
Positive predictive value (PPV)
Positive predictive value (PPV) will be measured as a percentage. PPV will reflect the percentage of times that each screening pathway matches a formal echocardiogram diagnosis.
Time frame: Baseline, 6 months, 1 year
Number of deaths
Number of deaths will include all-cause deaths.
Time frame: 1 year
Number of adverse cardiovascular events
Number of adverse cardiovascular events includes systolic heart failure, rt failure hospitalization.
Time frame: 1 year
Percentage of subjects to be diagnosed with decreased LVEF (left ventricular ejection fraction)
Percentage of subjects to be diagnosed with decreased LVEF will be determined by the percentage of subjects to have a LVEF lower than 50%.
Time frame: Baseline, 6 months,1 year
Percentage of subjects to be diagnosed with cardiac amyloidosis
Percentage of subjects to be diagnosed with cardiac amyloidosis will be determined by the number of subjects that have a positive AI-ECG or ultrasound. Cardiac amyloidosis is the buildup of protein in the heart muscle that affect the structure and function of the heart.
Time frame: Baseline, 6 months,1 year
Percentage of subjects to be diagnosed with aortic stenosis
Percentage of subjects to be diagnosed with aortic stenosis will be determined by the number of subjects that have a positive AI-ECG or ultrasound. Aortic stenosis is the narrowing of the aortic value decreasing the blood flow from heart to the aorta.
Time frame: Baseline, 6 months,1 year
Percentage of subjects to be diagnosed with hypertrophic cardiomyopathy
Percentage of subjects to be diagnosed with hypertrophic cardiomyopathy will be determined by the number of subjects that have a positive AI-ECG or ultrasound. Hypertrophic cardiomyopathy is the thickening of the heart muscle which leads to reduced blood flow.
Time frame: Baseline, 6 months,1 year
Plan to share: No
No publications or documents are linked to this record.
Started Apr 2025 (actual). Primary completion is estimated for Nov 2026, 19 months after the start.
Of 185 non-industry observational studies under Heart Diseases, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 118. This study's planned 19 months is below that.
Counting every sponsor, half of 239 studies reached it within 46 months; a quarter within 18 and three quarters within 95.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.